Valeant Pharmaceuticals Intl Inc news

   Watch this stock
Showing stories 1 - 10 of about 134   

Articles published

VRX 228.49 +0.25 (0.11%)
price chart
Valeant Pharmaceuticals International Inc. is now worth more than Toronto ...
Valeant is in talks to acquire Amoun Pharmaceutical Co., one of the largest drugmakers in Egypt, according to people with knowledge of the matter, Bloomberg reported May 20.
Valeant now worth more than TD Bank as drugmakers surge
Valeant challenges TD Bank to become Canada's second-largest stock  The Globe and Mail
Valeant Pharmaceuticals International Inc in advanced talks to buy Amoun ...
Valeant Pharmaceuticals International Inc. is in advanced negotiations to acquire Egyptian drugmaker Amoun Pharmaceutical Co.
Could the CEO of Valeant Pharmaceuticals Intl Inc. Be the Next Warren Buffett?  The Motley Fool Canada
Valeant Pharmaceuticals International, Inc. (VRX) Files Form 4 Insider ...  Insider Trading Report
Valeant Pharmaceuticals International Inc. is becoming the 800-pound gorilla ...
Scott Eells/Bloomberg Valeant Pharmaceuticals International Inc. chief executive Michael Pearson, has stated his company's goal is to become one of the top five largest drugmakers in the world by 2016, which means reaching a market value of at least ...
Valeant gains clout with support from big-betting hedge funds  Montreal Gazette
Canada Stocks Decline in Global Equities Slide; Air Canada Gains  Bloomberg
Valeant Pharmaceuticals International Inc CEO primed for more deals
Michael Pearson's penchant for acquisitions has helped catapult Valeant Pharmaceuticals International Inc. to the heavyweight ranks of the TSX Composite Index, and the company's chief executive officer shows no signs of slowing down the deal flow.
Billionaire John Paulson Doubles Down on Valeant Pharmaceuticals Intl Inc.  The Motley Fool Canada
Valeant Pharmaceuticals Announces 2015 Annual Meeting Results  Canada NewsWire (press release)
Is Valeant Pharmaceuticals Intl Inc. Another Berkshire Hathaway?
While the title might seem totally bombastic, Bill Ackman, the hedge fund manager of Pershing Square Capital, believes that Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) could actually be an early-stage Berkshire Hathaway. The reason Ackman ...
Robert Chaionn Insider Deal for 90938 Shares of Valeant Pharmaceuticals Intl ...
Insider Selling: Facebook Inc (FB), Valeant Pharmaceuticals Intl Inc (VRX ...  Bidness ETC
Valeant Pharmaceuticals International Inc wooing Egyptian drugmaker, wants to ...
In March, Valeant beat Endo International Plc in a bidding war to acquire Salix Pharmaceuticals Inc. for $11.1 billion.
Valeant in talks to buy Egyptian drugmaker Amoun Pharma: Bloomberg  Reuters UK
Valeant Said to Be in Talks to Acquire Egyptian Drugmaker Amoun  Bloomberg
Valeant Pharmaceuticals International Inc's bid for Salix Pharmaceuticals ...
Canadian Press//Ryan RemiorzValeant Pharmaceuticals International Inc's chief executive Mike Pearson agreed to buy bowel drug maker Salix Pharmaceuticals Ltd in late February for about US$10 billion, or US$158 all cash offer per share.
Valeant Comments On Endo Offer To Acquire Salix  PR Newswire (press release)
Endo offers about $11B for Salix, trumping Valeant
Should You Buy Valeant Pharmaceuticals Intl Inc. on the Salix Pharmaceuticals ...
It didn't take long for Valeant Pharmaceuticals Intl. Inc. (TSX:VRX)(NYSE:VRX) to start acquiring again after the recent failure at acquiring Allergan, Inc. Despite the fact the CEO talked about taking a few quarters to start paying down debt and ...
Valeant To Acquire Salix Pharmaceuticals For $158.00 Per Share In Cash  Canada NewsWire (press release)
Valeant agrees to buy Salix in $14.5B deal  CTV News
Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) and Zoetis Inc. (NYSE:ZTS) – A ...
All eyes are on Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) as Wall Street reported on Thursday that the drug maker might just carry out a potential acquisition of Zoetis Inc. (NYSE:ZTS).
Valeant Pharmaceuticals Intl Given Average Recommendation of "Buy" ...  Dakota Financial News
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Analyst Rating Update  Money Flow Index
As new Valeant CFO, merger expert Robert Rosiello ready to maintain M&A ...
MONTREAL - Valeant Pharmaceuticals International Inc's new Chief Financial Officer made his mark as an expert in healthcare mergers and acquisitions, and this is exactly what he wants to continue doing at Canada's largest publicly-traded drug company.
ValueAct Capital Discloses Sale of Shares of Valeant Pharmaceuticals ...  MarketWatch
Valeant Chooses Familiar CFO  Wall Street Journal (blog)